Onkologie. 2018:12(5):231-234 | DOI: 10.36290/xon.2018.042
Antiangiogenic therapy of lung cancer
- Pneumologická klinika UK 2. LF a FN Motol, Praha
One of the possibilities of anti-tumour treatment is the influence of tumour angiogenesis, triggering activation of thevascular endothelial growth factor (VEGFR) receptor, platelet growth factor (PDGFR) and fibroblast growth factor (FGFR).This treatment modality has also found its place in the treatment of advanced non-small cell lung cancer (NSCLC), whichis one of the most unfavourable tumours. First, bevacizumab was approved for treatment with NSCLC in combination withchemotherapy, later in the 2 nd line of treatment with nintedanib and ramucirumab in combination with chemotherapy.Recently, it has also been shown to be effective in combination with tyrosine kinase inhibitors receptor epidermal growthfactor (EGFR TKI) or immunotherapy.
Keywords: non-small cell lung cancer, antiangiogenic therapy, bevacizumab, nintedanib, ramucirumab, erlotinib, atezolizumab
Published: October 15, 2018 Show citation
References
- Sandler A, et al. Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer.NEJM 2006; 355: 2542-2550.
Go to original source... - Reck M, Kaiser R, Mellemgaard A, et al. LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15(2): 143-155. Go to original source...
- Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial The Lancet, 2014; 384(9944): 665-673. Go to original source...
Go to PubMed... - Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lungcancer harbouring EGFR mutations (JO25567): an open-label,randomised, multicentre, phase 2 study.Lancet Oncol 2014 Published Online August 28, 2014 http://dx.doi.org/10.1016/S1470-2045(14)70381-X Go to original source...
- Rosell R, Dafni U, Felip E, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017; 5(5): 435-444. Go to original source... Go to PubMed...
- Socinski MA, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 2018; 378: 2288-2301. Go to original source...